SCHEMBL1859157

SCHEMBL1859157

CCCCOC(=O)N1CCCC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.69
POLB P06746 3/20 0.69
LMNA P02545 1/20 0.69
ALDH1A1 P00352 7/20 0.50
KMT2A Q03164 3/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
HPGD P15428 3/20 0.50
MEN1 O00255 2/20 0.50
TDP1 Q9NUW8 1/20 0.48
HRH2 P25021 1/20 0.46
HRH1 P35367 1/20 0.46
ATM Q13315 1/20 0.45
TSHR P16473 2/20 0.44
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7838421 0.98 SMN1; SMN2 (0.67) SMN1; SMN2POLBLMNAALDH1A1KMT2A
SCHEMBL1826048 0.98 SMN1; SMN2 (0.67) SMN1; SMN2POLBLMNAALDH1A1KMT2A
SCHEMBL11492059 0.98 SMN1; SMN2 (0.67) SMN1; SMN2POLBLMNAALDH1A1KMT2A
SCHEMBL3634052 0.96 SMN1; SMN2 (0.69) SMN1; SMN2POLBLMNAALDH1A1KMT2A
SCHEMBL5405182 0.94 SMN1; SMN2 (0.62) SMN1; SMN2POLBLMNAALDH1A1KMT2A
Methyl Alcohol SCHEMBL27443089 0.94 SMN1; SMN2 (0.67) SMN1; SMN2POLBLMNAALDH1A1KMT2A
SCHEMBL19830587 0.92 LMNA (0.60) SMN1; SMN2POLBLMNAKMT2AL3MBTL1
SCHEMBL29037010 0.92 LMNA (0.60) SMN1; SMN2POLBLMNAKMT2AL3MBTL1
SCHEMBL5935756 0.92 LMNA (0.60) SMN1; SMN2POLBLMNAKMT2AL3MBTL1
SCHEMBL10700528 0.92 SMN1; SMN2 (0.60) SMN1; SMN2POLBLMNAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2576635-A1 FILM FORMING COATING COMPOSITIONS CONTAINING CARBOXAMIDE COALESCING SOLVENTS AND METHODS OF USE Stepan Company (US) 2013-04-10 EP claimed
WO-2011149830-A1 FILM FORMING COATING COMPOSITIONS CONTAINING CARBOXAMIDE COALESCING SOLVENTS AND METHODS OF USE STEPAN COMPANY (US) 2011-12-01 WO claimed
US-20250179066-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-06-05 US disclosed
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY AZEVAN PHARMACEUTICALS, INC. (US) 2024-04-11 US disclosed
WO-2024024703-A1 RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, AND SALT 東京応化工業株式会社 2024-02-01 WO disclosed
US-20240016946-A1 DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD. (CN) 2024-01-18 US disclosed
WO-2023228847-A1 RADIATION-SENSITIVE RESIN COMPOSITION AND PATTERN FORMATION METHOD JSR株式会社 2023-11-30 WO disclosed
WO-2023210520-A1 RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, AND COMPOUND 東京応化工業株式会社 2023-11-02 WO disclosed
WO-2023210472-A1 RESIST COMPOSITION AND RESIST PATTERN FORMING METHOD 東京応化工業株式会社 2023-11-02 WO disclosed
WO-2023171743-A1 RESIST COMPOSITION, METHOD FOR FORMING RESIST PATTERN, COMPOUND, AND POLYMER 東京応化工業株式会社 2023-09-14 WO disclosed
WO-2023171739-A1 RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, COMPOUND, AND POLYMER COMPOUND 東京応化工業株式会社 2023-09-14 WO disclosed
WO-1999054284-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-28 WO disclosed
WO-1999052365-A1 ANTICANCER AGENTS ELI LILLY AND COMPANY (US) 1999-10-21 WO disclosed
CN-1232399-A Cysteine protease inhibitors SMITHKLINE BEECHAM CORP (US) 1999-10-20 CN disclosed
CN-1145364-A Heterocyclic compounds and their preparation and use LILLY CO ELI (US) 1997-03-19 CN disclosed
EP-0588917-A4 1994-04-13 EP disclosed
EP-0588917-A1 ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LABORATORIES (US) 1994-03-30 EP disclosed
US-5220001-A Antitumor agents ZAIDAN HOJIM BISEIBUTSU DONG-A PHARM CO. (KR) 1993-06-15 US disclosed
WO-1992021339-A1 ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LABORATORIES (US) 1992-12-10 WO disclosed
US-4234484-A FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID HOECHST AKTIENGESELLSCHAFT (DE) 1980-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY FABP7, PYGB, CHAT SMN1; SMN2 114/4885POLB 3062/4885LMNA 451/4885
US-20250179066-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS MRPL21, WIZ, CFTR SMN1; SMN2 3678/4885POLB 2586/4885LMNA 2148/4885
US-20240016946-A1 DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR MRPL38, MRPS27, MRPS18A SMN1; SMN2 4622/4885POLB 1619/4885LMNA 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.